Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Dictionary of Cancer Terms

MET tyrosine kinase inhibitor PF-02341066  listen  (… TY-ruh-seen KY-nays in-HIH-bih-ter …)

  A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma kinase (ALK). It is also being studied in the treatment of other types of cancer. MET tyrosine kinase inhibitor PF-02341066 blocks the protein made by the mutated ALK gene. Blocking this protein may stop the growth and spread of cancer cells. MET tyrosine kinase inhibitor PF-02341066 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called crizotinib, PF-02341066, and Xalkori.

More Information